Understanding glycan-sensitive vs glycan-agnostic PD-1 antibodies using 3decision 2.0

This article by Marija Martini summarizes important studies on the programmed cell death-1 receptor (PD-1) glycosylation and its influence on immunotherapeutics discovery, using new features from the 3decision V2.0 release.

Read the full blog post >>

Previous
Previous

Discngine at Future Labs Live 2025 in Basel, Switzerland

Next
Next

3decision 2.0 milestone release